Emerging Policy Issues in Synthetic Biology

Publié par OECD, le 04 juin 2014

168 pages

Résumé

Synthetic biology is at such an early stage of development that there is no uniform agreement as yet about what it actually is. To some, it represents a natural extension of genetic engineering, and therefore is "business as usual". For others, it is a way to bring mass manufacturing out from the decades of biotechnology research. Currently the discipline is limited by the ability to synthesise DNA cost-effectively but this is a technical barrier that it is anticipated will be overcome. Synthetic biology raises a number of policy issues around R&D funding, company investment, PPP arrangements and innovative financing, infrastructure requirements, education and training, intellectual property (IP), regulation, and public engagement. In preparation for the continuing development and greater use of synthetic biology, some countries have started to prepare synthetic biology technical roadmaps and a global roadmap for the medium term would be an extremely useful policy tool. Technical roadmaps could both identify likely future policy requirements, and be a useful vehicle in public engagement.

Pôles de compétitivité, innovation et entrepreneuriat

Lituanie - Examen des politiques de l'éducation

Politique de l'environnement et comportement des menages

L'économie de la mer en 2030

L'espace à l'horizon 2030 - Relever les défis de la société de demain

Pour une meilleure approche régionale du développement en Afrique de l'Ouest : actes de la réunion spéciale du club du Sahel et de l'Afrique de l'Ouest, ACCRA (Ghana), 20-21 mai 2002

Cadre d'évaluation du PISA 2003 - Connaissance et compétences en mathématiques, lecture, science et résolution de problèmes

OECD guidelines on corporate governance of state-owned entreprises 2015

Critiques